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High in vitro lymphoproliferative responses were induced in humans and dogs by a recombinant Leishmania
(Leishmania) chagasi cysteine proteinase, with secretion of IFN- in asymptomatic subjects or of IFN-,
interleukin 4 (IL-4), and IL-10 in oligosymptomatic subjects. In contrast, responses of symptomatic patients
and dogs were lower, with production of IL-4 and IL-10.
Visceral leishmaniasis (VL) is caused by Leishmania (Leish-
mania) chagasi in South America, and dogs are the main res-
ervoir of the disease. Among the immunological changes found
with VL, those involving T cells and interleukin 10 (IL-10)
production have been correlated with pathology, whereas con-
trol of the infection has been associated with the production of
gamma interferon (IFN-) (3, 4, 5, 8, 13). Leishmania (L.)
infantum cysteine proteinases have been used for the evalua-
tion of humoral and cellular immune responses in human and
canine VL (9, 12). A recombinant cysteine proteinase from L.
(L.) chagasi, rLdccys1, expressed by the Ldccys1 gene (10) in
Escherichia coli, was shown to be a suitable tool for the diag-
nosis of American VL (6). The present study demonstrates
that rLdccys1 elicits cellular immune responses in naturally
infected humans and dogs in different stages of VL.
L. (L.) chagasi (MHOM/BR/1972/LD) amastigotes were iso-
lated from spleens of infected hamsters, as previously de-
scribed (2). The L. (L.) chagasi Ldccys1 was cloned and ex-
pressed as described elsewhere (6). The study population
included human and canine blood samples obtained from sub-
jects living in Teresina, Piauı´ State, Brazil, an area where VL is
endemic, and were classified as shown in Table 1. The human
and dog procedures were approved by the Ethical Committee
for Human and Animal Care at the Universidade Federal de
Sa˜o Paulo, Escola Paulista de Medicina. The lymphoprolifera-
tive assays were performed with peripheral blood mononuclear
cells (PBMC) purified by Ficoll-Hypaque density gradient cen-
trifugation. For in vitro proliferation assays, the cells were
cultured into 96-wells plates (1  106 cells/ml) in RPMI 1640
medium with 10% pooled human serum (R10) in the presence
of rLdccys1 (2.5 g/ml) or L. (L.) chagasi amastigote extracts
(AM) (equivalent to 1  107 amastigotes). After 96 h at 37°C
in 5% CO2, the cells were pulsed with 1 Ci of [
3H]thymidine/
well for 18 h, and [3H]thymidine uptake was determined after
filtration on glass fiber filters. Lymphoproliferative responses
were expressed as stimulation indexes (SI) determined by di-
viding the mean counts per minute for antigen-stimulated cells,
in triplicate, by the mean counts for the control medium. Stu-
dent’s t test was used with SigmaStat software to evaluate the
significance of the data (P  0.05). After stimulation with
rLdccys1, PBMC from asymptomatic, oligosymptomatic, symp-
tomatic, and treated patients proliferated with mean stimula-
tion indexes of 8.0, 6.25, 2.45, and 4.1, respectively, whereas
healthy individuals showed basal levels of lymphoproliferation.
Lower stimulation was obtained for PBMC from the same
patients with AM (SI of 2.5, 5.0, 2.1, and 2.0 from asymptom-
atic, oligosymptomatic, symptomatic, and treated patients, re-
spectively) (Fig. 1A). In PBMC from asymptomatic, oligo-
symptomatic, and symptomatic dogs, rLdccys1 induced SI
means of 11, 3.3, and 1.8, respectively, whereas lower re-
sponses were obtained with AM (SI of 2.2, 1.2, and 0.6 from
asymptomatic, oligosymptomatic, and symptomatic dogs, re-
spectively). Corroborating our results, the lymphoproliferative
responses stimulated by the recombinant L. (L.) infantum cys-
teine proteinase B (rCPB) in Iranian dogs with active VL were
weaker in symptomatic than in asymptomatic animals. How-
ever, in contrast to our results, asymptomatic dogs showed
higher lymphoproliferative responses to the total L. (L.) infan-
tum lysate than to rCPB. In addition, for asymptomatic dogs,
we found that higher lymphoproliferative responses were elic-
ited by rLdccys1 (SI 11) than by rCPB (SI 4.0) (9, 12). For
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TABLE 1. Classification of study population according to VL
clinical symptoms and isolation of L. (L.) chagasi
amastigotes from bone marrow
Patient group Clinicalsymptoma
Parasite
isolation
Noninfected (n  10)  No
asymptomatic (n  21)  Yes
oligosymptomatic (n  22)  Yes
symptomatic (n  25)  Yes
treated (n  23)  No
a , absence of clinical signs; , fever; , fever and splenomegaly;
, weight loss, splenomegaly, and hepatomegaly.
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evaluation of lymphokine production, 1 107 PBMC from VL
patients and dogs were cultured in 1 ml of R10 and maintained
for 72 h in the presence of 2.5 g/ml rLdccys1. Culture super-
natants were tested for IFN-, IL-4, and IL-10 using a specific
enzyme-linked immunosorbent assay. PBMC from asymptom-
atic patients secreted high levels of IFN- when stimulated
with rLdccys1 (1.722 ng/ml). Lower levels of IFN- (0.871
ng/ml) were produced by PBMC from oligosymptomatic pa-
tients, whereas this lymphokine was not detected in symptom-
atic individuals. IL-4 and IL-10 were secreted by PBMC from
oligosymptomatic patients (0.277 ng/ml and 0.317 ng/ml, re-
spectively), and a significant increase in the secretion of these
two lymphokines was detected in symptomatic individuals
(0.848 ng/ml and 0.725 ng/ml for IL-4 and IL-10, respectively).
No lymphokine secretion was found in the PBMC supernatants
from normal and treated patients (Table 2). These results
corroborate literature data which show that VL patients with a
controlled form of the disease display Th1-type lymphokines,
whereas immunosuppression and a Th2 profile predominate in
individuals with exacerbated disease (1, 8, 14). Secretion of
significant levels of IFN-, IL-4, and IL-10 by lymphocytes
from oligosymptomatic patients is in agreement with data
which showed both resistant (IFN-) and susceptible (IL-10)
profiles in this form of VL (7). PBMC from asymptomatic and
oligosymptomatic dogs secreted IFN-, whereas IL-4 and
IL-10 were released by PBMC from symptomatic animals (Ta-
ble 3). Lymphocytes from oligosymptomatic dogs did not se-
crete IL-4; however, IL-10 values were comparable in the su-
pernatants of PBMC from humans and dogs presenting
symptomatic and oligosymptomatic signs of VL. Few studies
have reported cytokine dosage in dogs with VL (15), impairing
comparison with our results. The production of nitric oxide
(NO) was also evaluated for the supernatants from human and
dog lymphocytes stimulated by rLdccys1, by use of the Griess
reagent. PBMC from asymptomatic and oligosymptomatic pa-
tients secreted significant levels of NO (108.42 M  19.22
M and 58.71 M  7.78 M, respectively), whereas symp-
tomatic and treated patients secreted lower NO concentrations
(19.22 M  0.8 M and 5.02 M  0.2 M, respectively)
(Fig. 2A). A similar relationship between NO production and
the clinical signs of VL was observed with PBMC cultures from
dogs stimulated with rLdccys1 (82.16 M  8.33 M, 25.21
M  7.44 M, and 7.79 M  0.34 M from asymptomatic,
oligosymptomatic, and symptomatic dogs, respectively) (Fig.
FIG. 1. Proliferative responses of PBMC recovered from normal, asymptomatic, oligosymptomatic, symptomatic, and treated humans (A) and
dogs (B) in the presence of rLdccys1 and AM. Data are representative of three experiments and are shown as mean SI  standard deviations. An
SI of 2.0 was considered a positive response (P  0.05).
TABLE 2. Lymphokine production by PBMC from normal and VL
patients stimulated by L. (L.) chagasi rLdccysa
Clinical manifestation
Cytokine production (ng/ml)
IFN- IL-4 IL-10
Noninfected (n  10) 0.011  0.002 0.003 0.001 0.017 0.002
Asymptomatic (n  21) 1.722 0.133 0.077 0.026 0.054 0.031
Oligosymptomatic (n 
22)
0.871  0.085 0.277 0.081 0.317 0.005
Symptomatic (n  25) 0.037  0.006 0.848 0.075 0.725 0.122
Treated (n  23) 0.012  0.002 0.008 0.001 0.013 0.001
a Supernatants were used at a 1:4 dilution. Results are the means for triplicate
wells and are representative of three experiments. Minimal values considered
from lymphokine dosages were as follows: IFN-, 0.0153 ng/ml; IL-4, 0.016
ng/ml; IL-10, 0.016 ng/ml.
TABLE 3. Lymphokine production by PBMC from normal and VL
dogs stimulated by L. (L.) chagasi rLdccysa
Clinical manifestation
Cytokine production (ng/ml)
IFN- IL-4 IL-10
Normal (n  6) 0.008  0.003 0.012 0.004 0.006 0.002
Asymptomatic (n  18) 0.541 0.134 0.062 0.029 0.026 0.008
Oligosymptomatic (n 
14)
0.174  0.032 0.061 0.008 0.310 0.027
Symptomatic (n  17) 0.036  0.006 0.461 0.053 0.814 0.241
a Supernatants were used at a 1:4 dilution. Results are the means for triplicate
wells and are representative of three experiments. Minimal values considered
from lymphokine dosages were as follows: IFN-, 0.0153 ng/ml; IL-4, 0.016
ng/ml; IL-10, 0.016 ng/ml.
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2B). The observed direct correlation between the secretion of
IFN- and NO during the development of VL in humans and
dogs has been previously reported (11, 16).
Overall, our results showed that the rLdccys1 antigen is a
suitable immunological marker for several stages of VL in
humans and dogs.
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FIG. 2. NO production. PBMC isolated from human (A) and dog (B) blood were cultured for 72 h in the presence of 2.5 g/ml rLdccys1, and
NO was assayed in the cellular supernatants as described previously. Results are shown as the means  standard deviations and are representative
of three experiments.
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